With an obesity green light already in hand, Eli Lilly is pushing for its newly launched Foundayo (orforglipron) to break into Type 2 diabetes. More: ADA: Lilly posts oral semaglutide-topping data as Foundayo speeds toward 2nd potential nod in diabetes
read moreEli Lilly emerged as the “clear winner from ADA,” according to RBC Capital Markets analyst Trung Hyunh, who added that “the field is getting more crowded—but Lilly is widening its lead.” More: With ADA in the books, analyst says Lilly
read moreActress Mariska Hargitay looks back on her late father’s multiple myeloma journey in BMS’ “Investigate Myeloma” campaign, highlighting its emerging CELMoD research. More: ‘Law & Order’ star Mariska Hargitay teams up with BMS to investigate multiple myeloma research in awareness
read moreFor Novo Nordisk, the launch of the company’s highly anticipated Wegovy pill at the start of the year—representing the first oral GLP-1 for obesity—marked an opportunity to recapture some of the chronic weight management market it had ceded to rival
read moreThe FDA has expanded the label for Pfizer’s Hympavzi, now including patients age 6 and older who have hemophilia A or B. The new expansion covers all patients 6 and older, regardless of their inhibitor status. The new nod also
read more
Phase 3 results highlight metabolic benefits alongside weight loss More: Survodutide trial data show targeted visceral and liver fat reductions Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals